BCM
FLXN

Bayesian Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Bayesian Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,325
Closed -$224K – 798
2019
Q3 		$224K Buy
16,325
+6,300
+63% +$74.8K 0.04% 424
2019
Q2 		$123K Buy
+10,025
New +$116K 0.03% 455

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bayesian Capital Management's FLXN Position: Q4 2019 in Review

Bayesian Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2019, closing a stake of 16,325 shares — an estimated $224K sold.

Bayesian Capital Management first reported a position in FLXN in Q2 2019 and held it in 2 quarters. The position peaked at $224K in Q3 2019. 133 funds tracked by Wall St. Rank hold FLXN as of Q4 2019.

  • Bayesian Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Bayesian Capital Management sold 16,325 Flexion Therapeutics, Inc. shares in Q4 2019, an estimated $224K.
  • Bayesian Capital Management first reported a position in Flexion Therapeutics, Inc. in Q2 2019 and held it in 2 quarters.
  • Bayesian Capital Management's Flexion Therapeutics, Inc. position peaked at $224K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2019.

Based on Bayesian Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.